Reuters -- Questcor Pharmaceuticals Inc said it expects third-quarter sales of its gel Acthar for treatment of infantile spasms (IS) to be about 20 percent lower than the 161 new, shipped and paid prescriptions in the second quarter.
Reuters -- Questcor Pharmaceuticals Inc said it expects third-quarter sales of its gel Acthar for treatment of infantile spasms (IS) to be about 20 percent lower than the 161 new, shipped and paid prescriptions in the second quarter.
